← Back to Search

Vitamin A Metabolite

Aerosolized 13 cis retinoic acid and Vitamin D for Anomia

Phase 4
Waitlist Available
Led By Amr Ahmed
Research Sponsored by Amr kamel khalil Ahmed
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks after softgel initiation
Awards & highlights

Summary

This trial is testing a Vitamin A mist to help adults who lost their sense of smell due to COVID-19. The treatment works by repairing and regenerating the cells in the nose that detect smells.

Eligible Conditions
  • Anomia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks after softgel initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks after softgel initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement of olfaction
Secondary outcome measures
Angiotensin-converting enzyme II (ACE2) expression in lungs and olfactory region
Frequency of adverse events and severe adverse events
Il-6 blood levels
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Aerosolized All trans retinoic acid and Vitamin DExperimental Treatment1 Intervention
Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized all trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Group II: Aerosolized 13 cis retinoic acid and Vitamin DExperimental Treatment1 Intervention
Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Group III: Standard therapyPlacebo Group1 Intervention
Standard therapy

Find a Location

Who is running the clinical trial?

Amr kamel khalil AhmedLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled
Kafrelsheikh UniversityLead Sponsor
125 Previous Clinical Trials
123,394 Total Patients Enrolled
Ministry of Health, Saudi ArabiaOTHER_GOV
28 Previous Clinical Trials
33,498 Total Patients Enrolled
~2609 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top